Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer.

Brown KK, Spinelli JB, Asara JM, Toker A.

Cancer Discov. 2017 Apr;7(4):391-399. doi: 10.1158/2159-8290.CD-16-0611. Epub 2017 Mar 2.

PMID:
28255083
2.

Understanding the Intersections between Metabolism and Cancer Biology.

Vander Heiden MG, DeBerardinis RJ.

Cell. 2017 Feb 9;168(4):657-669. doi: 10.1016/j.cell.2016.12.039. Review.

PMID:
28187287
3.

Rare syndromes of the head and face: mandibulofacial and acrofacial dysostoses.

Terrazas K, Dixon J, Trainor PA, Dixon MJ.

Wiley Interdiscip Rev Dev Biol. 2017 May;6(3). doi: 10.1002/wdev.263. Epub 2017 Feb 10. Review.

PMID:
28186364
4.

Microenvironment-derived factors driving metastatic plasticity in melanoma.

Kim IS, Heilmann S, Kansler ER, Zhang Y, Zimmer M, Ratnakumar K, Bowman RL, Simon-Vermot T, Fennell M, Garippa R, Lu L, Lee W, Hollmann T, Xavier JB, White RM.

Nat Commun. 2017 Feb 9;8:14343. doi: 10.1038/ncomms14343.

5.

Melanoma genome evolution across species.

Kansler ER, Verma A, Langdon EM, Simon-Vermot T, Yin A, Lee W, Attiyeh M, Elemento O, White RM.

BMC Genomics. 2017 Feb 7;18(1):136. doi: 10.1186/s12864-017-3518-8.

6.

An ongoing role for Wnt signaling in differentiating melanocytes in vivo.

Vibert L, Aquino G, Gehring I, Subkankulova T, Schilling TF, Rocco A, Kelsh RN.

Pigment Cell Melanoma Res. 2017 Mar;30(2):219-232. doi: 10.1111/pcmr.12568. Epub 2017 Mar 9.

7.

Review of the Genetic Basis of Jaw Malformations.

Ahmed MK, Ye X, Taub PJ.

J Pediatr Genet. 2016 Dec;5(4):209-219. Epub 2016 Oct 12. Review.

PMID:
27895973
8.

Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.

Murphy AG, Casey R, Maguire A, Tosetto M, Butler CT, Conroy E, Reynolds AL, Sheahan K, O'Donoghue D, Gallagher WM, Fennelly D, Kennedy BN, O'Sullivan J.

Sci Rep. 2016 Oct 14;6:34523. doi: 10.1038/srep34523.

9.

Zebrafish small molecule screens: Taking the phenotypic plunge.

Williams CH, Hong CC.

Comput Struct Biotechnol J. 2016 Sep 18;14:350-356. eCollection 2016. Review.

10.

Modeling human diseases: an education in interactions and interdisciplinary approaches.

Zon L.

Dis Model Mech. 2016 Jun 1;9(6):597-600. doi: 10.1242/dmm.025882.

11.

Additive reductions in zebrafish PRPS1 activity result in a spectrum of deficiencies modeling several human PRPS1-associated diseases.

Pei W, Xu L, Varshney GK, Carrington B, Bishop K, Jones M, Huang SC, Idol J, Pretorius PR, Beirl A, Schimmenti LA, Kindt KS, Sood R, Burgess SM.

Sci Rep. 2016 Jul 18;6:29946. doi: 10.1038/srep29946.

12.

Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish.

Mouti MA, Dee C, Coupland SE, Hurlstone AF.

Oncotarget. 2016 Jun 28;7(26):39654-39670. doi: 10.18632/oncotarget.9207.

13.

Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma.

Tan JL, Fogley RD, Flynn RA, Ablain J, Yang S, Saint-André V, Fan ZP, Do BT, Laga AC, Fujinaga K, Santoriello C, Greer CB, Kim YJ, Clohessy JG, Bothmer A, Pandell N, Avagyan S, Brogie JE, van Rooijen E, Hagedorn EJ, Shyh-Chang N, White RM, Price DH, Pandolfi PP, Peterlin BM, Zhou Y, Kim TH, Asara JM, Chang HY, Young RA, Zon LI.

Mol Cell. 2016 Apr 7;62(1):34-46. doi: 10.1016/j.molcel.2016.03.013.

14.

The Zebrafish as a Tool to Cancer Drug Discovery.

Huiting LN, Laroche F, Feng H.

Austin J Pharmacol Ther. 2015;3(2):1069. Epub 2015 May 4.

15.

A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation.

Kaufman CK, Mosimann C, Fan ZP, Yang S, Thomas AJ, Ablain J, Tan JL, Fogley RD, van Rooijen E, Hagedorn EJ, Ciarlo C, White RM, Matos DA, Puller AC, Santoriello C, Liao EC, Young RA, Zon LI.

Science. 2016 Jan 29;351(6272):aad2197. doi: 10.1126/science.aad2197. Epub 2016 Jan 28.

16.

Whole Body Melanoma Transcriptome Response in Medaka.

Schartl M, Shen Y, Maurus K, Walter R, Tomlinson C, Wilson RK, Postlethwait J, Warren WC.

PLoS One. 2015 Dec 29;10(12):e0143057. doi: 10.1371/journal.pone.0143057. eCollection 2015.

17.

Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer.

Langenau DM, Sweet-Cordero A, Wechsler-Reya RJ, Dyer MA.

Cancer Res. 2015 Dec 15;75(24):5176-86. doi: 10.1158/0008-5472.CAN-15-1308. Epub 2015 Dec 1. Review.

18.

Rational Design of Benzylidenehydrazinyl-Substituted Thiazole Derivatives as Potent Inhibitors of Human Dihydroorotate Dehydrogenase with in Vivo Anti-arthritic Activity.

Li S, Luan G, Ren X, Song W, Xu L, Xu M, Zhu J, Dong D, Diao Y, Liu X, Zhu L, Wang R, Zhao Z, Xu Y, Li H.

Sci Rep. 2015 Oct 7;5:14836. doi: 10.1038/srep14836.

19.

Ribosomopathies: Global process, tissue specific defects.

Yelick PC, Trainor PA.

Rare Dis. 2015 Apr 1;3(1):e1025185. doi: 10.1080/21675511.2015.1025185. eCollection 2015. Review.

20.

Preclinical mouse cancer models: a maze of opportunities and challenges.

Day CP, Merlino G, Van Dyke T.

Cell. 2015 Sep 24;163(1):39-53. doi: 10.1016/j.cell.2015.08.068. Review.

Supplemental Content

Support Center